

NHS Foundation Trust

Information Governance Department

Suite 9 Buckingham Row Brick Kiln Lane Wigan WN1 1XX

Email: foi@wwl.nhs.uk Web: www.wwl.nhs.uk

Ref: FOI/2025/10586

Date Received: 12th March 2025

Response Due: 9th April 2025

Date: 1st April 2025

Dear Sir/Madam

With reference to your request for information received on 28th February 2025, I can confirm in accordance with Section 1 (1) of the Freedom of Information Act 2000 that we do hold part of the information you have requested. A response to each part of your request is provided below.

In your request you asked:

- 1. Please provide the total number of patients treated in the last 6 months for:
 - Polycythaemia Vera (ICD10 code D45) = 32.
 - Myelofibrosis (ICD10 code D47.4) = 9.
 - Myelofibrosis (ICD10 code D47.4) patients aged 65 and older = 9.
- 2. How many patients were treated in the past 6 months (for any disease) with:
 - Ruxolitinib = 12.
 - Fedratinib = 0.
 - Momelotinib = <5.
- 3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases?
 - Myelofibrosis (ICD10 code D47.4) = 10.
 - Polycythaemia Vera (ICD10 code D45) = <5.
 - Other/Unknown = <5.
- 4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years?
 69.
 - Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? = 0.
 - Of these patients, how many were treated in the past 6 months with Interferon therapy? = 0.

- Of these patients, how many have received no active treatment in the past 6 months?
 This information is not recorded. The Trust's pharmacy department can only identify treated patients.
- 5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.

 No.

The Trust has a standard procedure of not releasing information when the data involved is less than 5. This is because we feel that such low numbers could make the individuals involved identifiable and therefore may cause undue harm and distress.

To disclose this information would:

- a) Contravene the Data Protection Act principles in that it would amount to unfair and possibly unlawful processing, as there was a legitimate expectation by the third parties that this information would remain confidential, and
- b) Disclosure may cause damage or distress to the individual(s) involved, and that damage or distress would be unwarranted (section 10 of the DPA).

If you are not entirely satisfied with this response, please do not hesitate to contact the Information Governance Department via the email address provided. If we do not hear from you within 40 days, we will assume that we have been able to accommodate your request under the Freedom of Information Act 2000.

Yours sincerely,

Gary Masterman

Associate Director of Pharmacy (Governance Assurance)

PLEASE NOTE:

If you are unhappy with the service you have received in relation to your request and wish to make a complaint or request a review of our decision, you should write to: Information Governance Department, Wrightington, Wigan and Leigh NHS Foundation Trust, Suite 9, Buckingham Row, Brick Kiln Lane, Wigan, WN1 1XX.

If you are not content with the outcome of your complaint, you may apply directly to the Information Commissioner for a decision at:

The Information Commissioner's Office Wycliffe House Water Lane Wilmslow Cheshire, SK9 5AF

Helpline number: 0303 123 111